Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · IEX Real-Time Price · USD
42.32
+2.81 (7.11%)
At close: May 1, 2024, 4:00 PM
43.64
+1.32 (3.12%)
After-hours: May 1, 2024, 7:56 PM EDT
Vera Therapeutics Employees
Vera Therapeutics had 51 employees on December 31, 2023. The number of employees increased by 5 or 10.87% compared to the previous year.
Employees
51
Change (1Y)
5
Growth (1Y)
10.87%
Revenue / Employee
n/a
Profits / Employee
-$1,882,157
Market Cap
2.32B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 51 | 5 | 10.87% |
Dec 31, 2022 | 46 | 9 | 24.32% |
Dec 31, 2021 | 37 | 9 | 32.14% |
Dec 31, 2020 | 28 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Teladoc Health | 5,600 |
CONMED | 4,000 |
Guardant Health | 1,779 |
Inari Medical | 1,300 |
Privia Health Group | 1,102 |
Denali Therapeutics | 445 |
Arvinas | 445 |
Deciphera Pharmaceuticals | 355 |
VERA News
- 6 weeks ago - Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference - GlobeNewsWire
- 3 months ago - Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - GlobeNewsWire
- 3 months ago - Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock - GlobeNewsWire
- 3 months ago - Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock - GlobeNewsWire
- 3 months ago - Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - GlobeNewsWire
- 3 months ago - Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy - GlobeNewsWire
- 4 months ago - Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. - GlobeNewsWire